{"entity":{"id":"nct07178730","kind":"trial","name":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","aka":["ADAPT-TN-IV"],"tldr":"A phase 3 trial of sacituzumab govitecan in triple-negative breast cancer, run by Women's Cancer Study Group GmbH, not yet recruiting.","summary":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer is a phase 3, randomised interventional study registered as NCT07178730 by Women's Cancer Study Group GmbH, with a registry enrolment figure of 765 participants, started 2026-08-30 and due to reach its primary completion in 2033-03-31. Interventions recorded: Sacituzumab govitecan; Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]; SoC Chemotherapy. Conditions listed: Breast Cancer; Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: \"TNBC: ER = 0%, PR = 0%, and HER2- (i\". Sites: Germany. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07178730","url":"https://clinicaltrials.gov/study/NCT07178730"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07178730","phase":"3","setting":"NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","sponsor":"Women's Cancer Study Group GmbH","enrolled":765,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07178730/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}